var data={"title":"Echocardiographic recognition of cardiomyopathies","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Echocardiographic recognition of cardiomyopathies</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/contributors\" class=\"contributor contributor_credentials\">Nelson B Schiller, MD, FACC, FRCP, FASE</a></dd><dd><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/contributors\" class=\"contributor contributor_credentials\">Xiushui Ren, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/contributors\" class=\"contributor contributor_credentials\">Bryan Ristow, MD, FACC, FASE, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/contributors\" class=\"contributor contributor_credentials\">Warren J Manning, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/contributors\" class=\"contributor contributor_credentials\">Susan B Yeon, MD, JD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 22, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H15920411\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiomyopathy is defined as a disease of heart muscle. Cardiomyopathies include a variety of myocardial disorders that manifest with various structural and functional phenotypes with familial and nonfamilial types. This topic will review the echocardiographic features of the various types of cardiomyopathy. The general evaluation of the patient with heart failure or cardiomyopathy is discussed separately. (See <a href=\"topic.htm?path=determining-the-etiology-and-severity-of-heart-failure-or-cardiomyopathy\" class=\"medical medical_review\">&quot;Determining the etiology and severity of heart failure or cardiomyopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H116968825\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The classification of cardiomyopathies is reviewed separately. In summary, morphological and functional attributes have been described by the 2006 American Heart Association and 2008 European Society of Cardiology classification systems (<a href=\"image.htm?imageKey=CARD%2F64479%7ECARD%2F74268\" class=\"graphic graphic_table graphicRef64479 graphicRef74268 \">table 1A-B</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Heart disease secondary to coronary artery, valvular, or congenital heart disease is excluded from the cardiomyopathy classification. However, in clinical practice, the terms &quot;ischemic,&quot; &quot;valvular,&quot; and &quot;hypertensive cardiomyopathy&quot; have been used commonly. There are five types of cardiomyopathy that are each recognized by echocardiography [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In the MOGE(S) classification endorsed by the World Heart Federation, cardiomyopathy is categorized by the following characteristics: morphofunctional (M), organ involvement (O), genetic or familial inheritance (G), etiological annotation (E), and stage (S) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;</a>.)</p><p>The five types of morphofunctional cardiomyopathy are as follows (<a href=\"image.htm?imageKey=CARD%2F64479%7ECARD%2F74268\" class=\"graphic graphic_table graphicRef64479 graphicRef74268 \">table 1A-B</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dilated cardiomyopathy arising as primary myocardial disease of unknown etiology or as disorders of toxic, familial, or infective origin. In clinical practice, ischemic cardiomyopathy is frequently viewed as a type of dilated cardiomyopathy, although current major society classification systems exclude it [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=causes-of-dilated-cardiomyopathy\" class=\"medical medical_review\">&quot;Causes of dilated cardiomyopathy&quot;</a> and <a href=\"topic.htm?path=familial-dilated-cardiomyopathy-prevalence-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertrophic cardiomyopathy, including various causes of increased left ventricular wall thickness not caused by hypertension or valve disease (see <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;</a>). Restrictive cardiomyopathy, including cardiac amyloidosis and endomyocardial fibrosis. (See <a href=\"topic.htm?path=idiopathic-restrictive-cardiomyopathy\" class=\"medical medical_review\">&quot;Idiopathic restrictive cardiomyopathy&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of amyloid cardiomyopathy&quot;</a> and <a href=\"topic.htm?path=endomyocardial-fibrosis\" class=\"medical medical_review\">&quot;Endomyocardial fibrosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arrhythmogenic right ventricular cardiomyopathy. (See <a href=\"topic.htm?path=arrhythmogenic-right-ventricular-cardiomyopathy-anatomy-histology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Arrhythmogenic right ventricular cardiomyopathy: Anatomy, histology, and clinical manifestations&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restrictive cardiomyopathy. (See <a href=\"topic.htm?path=idiopathic-restrictive-cardiomyopathy\" class=\"medical medical_review\">&quot;Idiopathic restrictive cardiomyopathy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unclassified cardiomyopathy, including ventricular noncompaction and stress cardiomyopathy. (See <a href=\"topic.htm?path=isolated-left-ventricular-noncompaction\" class=\"medical medical_review\">&quot;Isolated left ventricular noncompaction&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy&quot;</a>.)</p><p/><p>Cardiomyopathies should be differentiated from exercise-induced cardiac remodeling (EICR), or so-called athlete&rsquo;s heart. EICR may be characterized by mild and symmetric wall thickening associated with cavity dilatation, and with high mitral inflow E velocities [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/4\" class=\"abstract_t\">4</a>]. Right ventricular enlargement has been observed in Olympic athletes, meeting a criterion for ARVC in 32 percent, and caution must be utilized not to classify these individuals as abnormal. Left atrial enlargement may also occur with EICR [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/5\" class=\"abstract_t\">5</a>]. Doppler tissue imaging and speckle tracking show promise in identifying normal function in EICR [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation#H2599226\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;, section on 'Athlete's heart'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DILATED CARDIOMYOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of one or both ventricles [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/6\" class=\"abstract_t\">6</a>]. Dilated cardiomyopathy is readily identified by echocardiography when it is fully developed but is more difficult to detect in its early stages. Without the clinical history, patient examination, and other diagnostic test results, echocardiography alone is often unable to establish the cause of myocardial disease. (See <a href=\"topic.htm?path=causes-of-dilated-cardiomyopathy\" class=\"medical medical_review\">&quot;Causes of dilated cardiomyopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Echocardiographic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most distinctive two-dimensional (2D) echocardiographic findings in a dilated cardiomyopathy are left ventricular (LV) spherical dilatation, normal or reduced wall thickness, poor systolic wall thickening, <span class=\"nowrap\">and/or</span> reduced inward endocardial systolic motion (<a href=\"image.htm?imageKey=CARD%2F58760\" class=\"graphic graphic_figure graphicRef58760 \">figure 1</a> and <a href=\"image.htm?imageKey=CARD%2F65679%7ECARD%2F67315%7ECARD%2F50731%7ECARD%2F66421\" class=\"graphic graphic_diagnosticimage graphicRef65679 graphicRef67315 graphicRef50731 graphicRef66421 \">image 1A-D</a>). All of the systolic indices are reduced, including LV fractional shortening, fractional area change, and ejection fraction (<a href=\"image.htm?imageKey=CARD%2F78668%7ECARD%2F75021%7ECARD%2F68493\" class=\"graphic graphic_movie graphicRef78668 graphicRef75021 graphicRef68493 \">movie 1A-C</a>). Four chamber cardiac enlargement is often present (<a href=\"image.htm?imageKey=CARD%2F67315%7ECARD%2F50731%7ECARD%2F66421\" class=\"graphic graphic_diagnosticimage graphicRef67315 graphicRef50731 graphicRef66421 \">image 1B-D</a>).</p><p>On M-mode echocardiography, additional features related to systolic dysfunction are increased separation of the mitral leaflet E point from the septum, poor mitral valve opening, poor aortic valve opening and early closure from a reduced stroke volume, and poor systolic aortic root motion (<a href=\"image.htm?imageKey=CARD%2F58760\" class=\"graphic graphic_figure graphicRef58760 \">figure 1</a> and <a href=\"image.htm?imageKey=CARD%2F66421%7ECARD%2F66756%7ECARD%2F63276%7ECARD%2F53355\" class=\"graphic graphic_diagnosticimage graphicRef66421 graphicRef66756 graphicRef63276 graphicRef53355 \">image 1D-G</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/7\" class=\"abstract_t\">7</a>]. A two-dimensional image of a normal heart in a young athlete with a slow heart rate may qualitatively suggest dilated cardiomyopathy. However, the M-mode will be normal and not display any of the above features.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Left ventricular volume</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based on the American Society of Echocardiography guidelines, quantitative measurements should be obtained for accurate evaluation of cardiac chamber sizes. While linear (M-mode) measurements are useful, they may not reflect true cardiac dimensions, especially in distorted ventricles. For this reason, linear derived volumetric measurements are no longer recommended [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"abstract_t\">8</a>]. In patients with dilated cardiomyopathy, the LV end-diastolic volume index often exceeds 100 <span class=\"nowrap\">mL/m<sup>2</sup></span> (upper normal is 74 <span class=\"nowrap\">mL/m<sup>2</sup></span> in men and 61 <span class=\"nowrap\">mL/m<sup>2</sup></span> in women) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"abstract_t\">8</a>]. The LV ejection fraction, derived from the end-systolic volume (ESV) and end-diastolic volume (EDV) determinations can, at times, fall below 20 percent, but is usually between 20 and 40 percent (normal &ge;52 percent in men and &ge;54 percent in women) (<a href=\"image.htm?imageKey=CARD%2F72326\" class=\"graphic graphic_diagnosticimage graphicRef72326 \">image 2</a> and <a href=\"image.htm?imageKey=CARD%2F68362%7ECARD%2F70139\" class=\"graphic graphic_figure graphicRef68362 graphicRef70139 \">figure 2A-B</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Despite the reduced LV ejection fraction, cardiac output calculations (stroke volume times heart rate) are frequently normal. There are two reasons for this finding. First, patients with cardiomyopathy frequently have elevated heart rates. Second, since the stroke volume is equal to the product of the LV end-diastolic volume and ejection fraction, the effect of a low ejection fraction can be counterbalanced by an elevation in end-diastolic volume. As an example, a patient with an end-diastolic volume of 200 mL, an ejection fraction of 30 percent, and a heart rate of 100 beats per minute has a cardiac output of 6 <span class=\"nowrap\">L/min</span>. In large hearts, accurate measurement of volume and their reproducibility are enhanced by using a microbubble contrast agent to improve detection of the boundary between the myocardium and blood pool.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">End-systolic volume index</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We routinely measure the LV end-systolic volume index (ESVI) because it provides important information in several clinical settings.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An ESVI that rises progressively from normal (&lt;31 <span class=\"nowrap\">mL/m<sup>2</sup></span> in men and &lt;24 <span class=\"nowrap\">mL/m<sup>2</sup></span> in women is an important clinical indicator of deteriorated global function [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/9\" class=\"abstract_t\">9</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with ischemic cardiomyopathy who have global dysfunction with segmental evidence of infarction, an ESVI of 45 <span class=\"nowrap\">mL/m<sup>2</sup></span> identifies patients with a poor outcome [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/10\" class=\"abstract_t\">10</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the later Heart and Soul study, the risk of an adverse outcome began to increase sharply once the end systolic volume exceeded 25 <span class=\"nowrap\">mL/m<sup>2</sup></span> [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Right ventricle</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Involvement of the right heart is important because it implies pulmonary hypertension <span class=\"nowrap\">and/or</span> right ventricular failure secondary to either pulmonary pressure elevation or to primary involvement of the right ventricular myocardium in the pathologic process. The prognosis is considerably worsened when there is right ventricular dilatation <span class=\"nowrap\">and/or</span> a reduced right ventricular ejection fraction [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/11,12\" class=\"abstract_t\">11,12</a>]. A useful and easily obtained measurement of right ventricular function is the tricuspid annular plane systolic excursion, also called TAPSE, an expression of longitudinal muscle function or descent of the right ventricular cardiac base. In one report, an excursion &le;14 mm added significant prognostic information to other clinical and echocardiographic findings in dilated cardiomyopathy [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"topic.htm?path=predictors-of-survival-in-heart-failure-with-reduced-ejection-fraction#H7\" class=\"medical medical_review\">&quot;Predictors of survival in heart failure with reduced ejection fraction&quot;, section on 'Right ventricular function'</a>.)</p><p>Gradients of tricuspid regurgitation and end diastolic pulmonary regurgitation correlate with pulmonary artery systolic and diastolic pressures, and have been shown to predict heart failure hospitalization and mortality in patients with coronary artery disease [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Left atrium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The left atrial end-systolic volume index may be increased and often exceeds 50 <span class=\"nowrap\">mL/m<sup>2</sup></span> (upper limits of normal approximately 34 <span class=\"nowrap\">mL/m<sup>2</sup>)</span> [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"abstract_t\">8</a>]. Data suggest that minimal atrial volume (at ventricular end-diastole) may be more predictive of outcomes than maximal left atrial volume (at ventricular end-systole) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/15\" class=\"abstract_t\">15</a>]. Left atrial volume estimates from biplane 2D measurements are more accurate than single linear dimensions for measuring left atrial size [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Doppler echocardiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Doppler has been used in dilated cardiomyopathy to measure decreased stroke volume. The velocity time integral of the LV outflow tract is decreased (&lt;18 cm) in this disorder (<a href=\"image.htm?imageKey=CARD%2F81391\" class=\"graphic graphic_diagnosticimage graphicRef81391 \">image 3</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/17\" class=\"abstract_t\">17</a>]. In addition, acceleration or deceleration of the mitral regurgitant jet can be used as an analog of <span class=\"nowrap\">dP/dT</span> (ie, the change in LV pressure over time) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/18\" class=\"abstract_t\">18</a>]. As an example, one study of 61 patients found that <span class=\"nowrap\">dP/dT</span> &lt;600 <span class=\"nowrap\">mmHg/sec</span> and <span class=\"nowrap\">-dP/dT</span> &lt;450 <span class=\"nowrap\">mmHg/sec</span> identified a high risk group with a reduced event-free survival [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Mitral regurgitation is a constant feature of dilated cardiomyopathy and is usually mild to moderate in severity but, on occasion, may be severe. The pathophysiology of mitral regurgitation in dilated cardiomyopathy is usually not due to organic leaflet disease but rather due to abnormal leaflet tethering mandated by the change in LV shape from ellipsoid to spherical. As cardiomyopathy progresses, the point of leaflet coaptation migrates from its normal basal location to a spot deeper in the LV cavity. (See <a href=\"topic.htm?path=echocardiographic-evaluation-of-the-mitral-valve\" class=\"medical medical_review\">&quot;Echocardiographic evaluation of the mitral valve&quot;</a>.)</p><p>Evaluation of mitral inflow patterns can identify patients with restrictive physiology due to diastolic dysfunction (<a href=\"image.htm?imageKey=CARD%2F59321\" class=\"graphic graphic_waveform graphicRef59321 \">waveform 1</a> and <a href=\"image.htm?imageKey=CARD%2F72146\" class=\"graphic graphic_table graphicRef72146 \">table 2</a>) (see <a href=\"topic.htm?path=echocardiographic-evaluation-of-left-ventricular-diastolic-function\" class=\"medical medical_review\">&quot;Echocardiographic evaluation of left ventricular diastolic function&quot;</a>). Restrictive or pseudonormal diastolic inflow patterns connote a poor prognosis and aid in guiding treatment [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/20-24\" class=\"abstract_t\">20-24</a>]. Patients with dilated cardiomyopathy have abnormally low diastolic suction and blunted capacity to recruit suction [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/25\" class=\"abstract_t\">25</a>].</p><p>The pulmonary vein flow signal should always be sought as an adjunct to the mitral inflow pattern. Abnormal pulmonary venous systolic flow patterns have been shown to correlate with future development of pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/26\" class=\"abstract_t\">26</a>]. Loss of the systolic dominant flow pattern suggests elevated filling pressure. Pulmonary venous flow reversal duration minus mitral inflow duration at atrial contraction &gt;30 ms predicts mortality and hospitalization [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/27\" class=\"abstract_t\">27</a>]. Similarly, Doppler tissue imaging has patterns associated with elevated LV filling pressures. (See <a href=\"topic.htm?path=predictors-of-survival-in-heart-failure-with-reduced-ejection-fraction#H5\" class=\"medical medical_review\">&quot;Predictors of survival in heart failure with reduced ejection fraction&quot;, section on 'Concomitant diastolic dysfunction'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Cardiac synchrony</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echocardiographic methods of evaluation for LV dyssynchrony include: M-mode septal to posterior wall motion delay, pre-ejection right and LV time intervals, Doppler tissue imaging delay, strain, strain rate, and tissue tracking [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/28-31\" class=\"abstract_t\">28-31</a>]. </p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Features of specific types of dilated cardiomyopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although echocardiography cannot distinguish the specific cause of dilated cardiomyopathy, certain types of disease processes have characteristic echocardiographic features. Dilated LVs may occur after chemotherapy, peripartum, tachycardia-mediated, premature ventricular contraction-mediated (generally &gt;20,000 PVCs in 24 hours or &gt;10 percent of recorded beats on Holter), thyrotoxic, muscular dystrophy associated cardiomyopathy, among other causes.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Ischemic cardiomyopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, ischemic heart disease is not considered a type of cardiomyopathy in formal classification systems, although the term &quot;ischemic cardiomyopathy&quot; is commonly used clinically to describe significantly impaired LV function that results from coronary artery disease. Wall motion abnormalities may be due to previous myocardial infarction <span class=\"nowrap\">and/or</span> associated with multivessel coronary artery disease. In both ischemic and idiopathic forms, LV wall motion abnormalities and the intensity of scarring can be segmentally variable or heterogeneous. Ischemic cardiomyopathy is often associated with regional remodeling, which is characterized by local segments that have their own radius of curvature. Ischemic cardiomyopathy also tends to have areas of endocardial brightening or scarring in infarcted areas.</p><p>Diagnosis of ischemic cardiomyopathy is discussed separately. (See <a href=\"topic.htm?path=ischemic-cardiomyopathy-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Ischemic cardiomyopathy: Treatment and prognosis&quot;</a>.)</p><p>Other disease states that can lead to regional wall motion abnormalities include sarcoidosis, tuberculosis, arrhythmogenic right ventricular cardiomyopathy (which may also involve the LV), stress-induced cardiomyopathy, and Chagas disease. </p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Chagasic cardiomyopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic Chagas cardiomyopathy is discussed separately. In relatively early stages of cardiac involvement, segmental wall motion abnormalities may be seen, including LV apical aneurysm and less commonly inferolateral wall thinning and scar formation. More advanced disease is characterized by global ventricular dilation and diffuse hypokinesis. (See <a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">HYPERTROPHIC CARDIOMYOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertrophic cardiomyopathy is characterized by increased left ventricular (LV) mass, which is quantitated by determining the wall thicknesses and estimating the LV wall mass. When these findings are present without apparent etiology, the cause of hypertrophy in the majority of cases is mutation in a gene encoding cardiac sarcomeric proteins. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;</a> and <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-gene-mutations-and-clinical-genetic-testing\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing&quot;</a>.)</p><p>The echocardiographic diagnosis of HCM is based upon the finding of an otherwise unexplained hypertrophied, nondilated LV [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/32\" class=\"abstract_t\">32</a>]. A septal wall thickness &ge;15 mm has been commonly used to diagnose HCM (both <span class=\"nowrap\">ACC/AHA</span> and ESC guidelines), although other causes for hypertrophy must be excluded and some patients with HCM do not meet this threshold for septal thickness [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/33,34\" class=\"abstract_t\">33,34</a>]. The degree and distribution of left ventricular hypertrophy (LVH) in hypertrophic cardiomyopathy are variable, and include septal hypertrophy with or without obstruction to LV outflow, concentric hypertrophy, apical hypertrophy, hypertrophy of the LV free wall, and right ventricular hypertrophy (<a href=\"image.htm?imageKey=CARD%2F58156\" class=\"graphic graphic_figure graphicRef58156 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/11\" class=\"abstract_t\">11</a>]. One characteristic pattern is asymmetric septal hypertrophy (ASH) with wall thickness greatest at the basal septum [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/35,36\" class=\"abstract_t\">35,36</a>]. ASH is recognized by a septal to posterior wall ratio of 1.5 to 1. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation#H4\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;, section on 'Echocardiography'</a>.)</p><p>In a more unusual and often more clinically benign variant of HCM, the apex is the site of the greatest hypertrophy [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/37-39\" class=\"abstract_t\">37-39</a>]. Apical hypertrophy is more difficult to identify by echocardiography because the apical myocardium is more difficult to image (<a href=\"image.htm?imageKey=CARD%2F51194\" class=\"graphic graphic_diagnosticimage graphicRef51194 \">image 4</a>). When this condition is suspected (eg, by finding deeply inverted precordial T waves on ECG), it is helpful to use an echocardiographic contrast agent to confirm the diagnosis and identify the small apical aneurysm that may form distal to the obstruction [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/40\" class=\"abstract_t\">40</a>]. Cardiac magnetic resonance imaging is a preferred imaging test for <span class=\"nowrap\">identification/exclusion</span> of the apical hypertrophic syndrome since it can detect apical aneurysms missed by echocardiography. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-morphologic-variants-and-the-pathophysiology-of-left-ventricular-outflow-tract-obstruction#H3851897598\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction&quot;, section on 'Apical HCM'</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Echocardiographic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The echocardiogram with Doppler is the most practical means to assess the hemodynamics of HCM. Approximately 20 to 25 percent of patients have a resting left ventricular outflow tract (LVOT) gradient of greater than 30 mmHg [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/41\" class=\"abstract_t\">41</a>]. However, when the obstruction is dynamic (ie, provocable but mild or absent at rest), the task of the echocardiographic laboratory is more difficult. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;</a> and <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-morphologic-variants-and-the-pathophysiology-of-left-ventricular-outflow-tract-obstruction\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction&quot;</a>.)</p><p>Use of Doppler techniques, particularly continuous wave, is mandatory. This modality is typically used to measure the systolic flow velocity in the LVOT and mid cavity at rest and during maneuvers (eg, Valsalva; normal 0.9 <span class=\"nowrap\">m/sec)</span> (<a href=\"image.htm?imageKey=CARD%2F67484\" class=\"graphic graphic_figure graphicRef67484 \">figure 4</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/42,43\" class=\"abstract_t\">42,43</a>]. Doppler in this setting will also enable the recognition of dynamic mitral regurgitation that often appears with a posteriorly directed jet in concert with outflow tract obstruction. Patients with LVOT obstruction often have the following features:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymmetric septal hypertrophy (<a href=\"image.htm?imageKey=CARD%2F78895%7ECARD%2F70534%7ECARD%2F78856\" class=\"graphic graphic_diagnosticimage graphicRef78895 graphicRef70534 graphicRef78856 \">image 5A-C</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systolic anterior motion of the mitral valve (SAM) (<a href=\"image.htm?imageKey=CARD%2F55693%7ECARD%2F50651\" class=\"graphic graphic_diagnosticimage graphicRef55693 graphicRef50651 \">image 6A-B</a> and <a href=\"image.htm?imageKey=CARD%2F79426%7ECARD%2F65618\" class=\"graphic graphic_movie graphicRef79426 graphicRef65618 \">movie 2A-B</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Crowding of the mitral apparatus by the LVOT (<a href=\"image.htm?imageKey=CARD%2F50651\" class=\"graphic graphic_diagnosticimage graphicRef50651 \">image 6B</a> and <a href=\"image.htm?imageKey=CARD%2F65618\" class=\"graphic graphic_movie graphicRef65618 \">movie 2B</a> and <a href=\"image.htm?imageKey=CARD%2F51424\" class=\"graphic graphic_diagnosticimage graphicRef51424 \">image 7</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Partial early systolic closure or notching of the aortic valve (<a href=\"image.htm?imageKey=CARD%2F75078\" class=\"graphic graphic_diagnosticimage graphicRef75078 \">image 8</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Calcification of the mitral annulus frequently accompanies hypertrophic cardiomyopathy, and, in some patients, this finding is the only clue to the potential for dynamic outflow tract obstruction. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-morphologic-variants-and-the-pathophysiology-of-left-ventricular-outflow-tract-obstruction\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mitral regurgitation often accompanies obstruction and the mitral regurgitation jet needs to be distinguished from the gradient jet.</p><p/><p class=\"headingAnchor\" id=\"H348986279\"><span class=\"h3\">Strain echocardiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Strain is measured by speckled-tracking measures, both global and regional ventricular function, and can detect reduced myocardial function in HCM [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/44,45\" class=\"abstract_t\">44,45</a>]. It also correlates with myocardial fibrosis and predicts ventricular arrhythmias [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/46\" class=\"abstract_t\">46</a>]. In addition, mechanical dispersion (defined as the standard deviation of time to peak negative strain) was significantly increased in HCM patients and was both related to amount of fibrosis and was an independent predictor of arrhythmia [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/47\" class=\"abstract_t\">47</a>]. Patients with HCM also have significantly lower longitudinal systolic strain, systolic strain rate, and early diastolic strain rate as compared with concentric hypertrophy due to systemic hypertension [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/48\" class=\"abstract_t\">48</a>]. Recognition of HCM may be facilitated by recording of strain data in a polar map, which have different patterns among different types of cardiomyopathy [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/49\" class=\"abstract_t\">49</a>]. </p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Provocative maneuvers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whenever obstructive or nonobstructive HCM is suspected but not overt, it is often desirable to perform some sort of intervention or provocation during the echocardiographic examination; the most frequently used maneuver is the Valsalva maneuver and the most common pharmacologic intervention is <a href=\"topic.htm?path=amyl-nitrite-drug-information\" class=\"drug drug_general\">amyl nitrite</a> inhalation (<a href=\"image.htm?imageKey=CARD%2F51424\" class=\"graphic graphic_diagnosticimage graphicRef51424 \">image 7</a>). (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of Doppler techniques, particularly continuous wave, is mandatory. This modality is typically used to measure the systolic flow velocity in the LVOT and mid cavity at rest and during maneuvers (normal 0.9 <span class=\"nowrap\">m/sec)</span> [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/42,43\" class=\"abstract_t\">42,43</a>]. Doppler in this setting will also enable the recognition of dynamic mitral regurgitation that often appears in concert with outflow tract obstruction. Distinguishing mitral regurgitation from an outflow tract gradient can be challenging for the sonographer.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systolic anterior movement of the mitral valve (SAM) on two-dimensional and M-mode imaging provides independent evidence of dynamic obstruction, particularly if there is also contact of the mitral leaflet tip and the septum; the more severe the obstruction, the more prolonged the contact (<a href=\"image.htm?imageKey=CARD%2F55693%7ECARD%2F50651\" class=\"graphic graphic_diagnosticimage graphicRef55693 graphicRef50651 \">image 6A-B</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p>If obstruction worsens with provocation, SAM will also worsen. SAM is graded as follows:</p><p> &#160;0 = absent</p><p> &#160;1+ = present, with a minimum distance between the mitral valve and ventricular septum during systole &gt;10 mm</p><p> &#160;2+ = without mitral-septal contact, but with a distance of &lt;10 mm between the mitral valve and septum</p><p> &#160;3+ = brief mitral-septal contact (&lt;30 percent of echocardiographic systole)</p><p> &#160;4+ = prolonged apposition of the mitral valve leaflet with the septum (&gt;30 percent of echocardiographic systole)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inspection of the aortic valve at the peak of provocation will provide secondary evidence of obstruction by demonstrating early systolic closure (producing notching, also known as a peak and dome configuration on M-mode echocardiography) (<a href=\"image.htm?imageKey=CARD%2F75078\" class=\"graphic graphic_diagnosticimage graphicRef75078 \">image 8</a>).</p><p/><p>A Valsalva maneuver is usually performed first, and if it fails to provoke changes, <a href=\"topic.htm?path=amyl-nitrite-drug-information\" class=\"drug drug_general\">amyl nitrite</a> inhalation may sometimes be used. During this more vigorous provocation the same structures are monitored. It is ideal during any intervention to have someone performing auscultation. If technical problems interfere with echocardiography or Doppler, detection of a new or worsening murmur, particularly if intense, may be sufficient to identify a culprit condition. Exercise testing may also be used to evaluate this condition. We use supine bicycle so that it is possible to image the heart and sample flow by Doppler during and after the stress test. In this way changes in gradient, severity of mitral regurgitation, and rhythm may be sought. Note that the dynamic outflow gradient often does not worsen until the immediate post-exercise period. This behavior of dynamic obstruction often mimics a common symptom complex in HCM.</p><p>In a study of HCM patients with and without obstruction, independent outcome predictors were global longitudinal strain &le;15 percent and peak exercise LVOT gradient &ge;50 mmHg (hazard ratios, 3.8 and 3.3, respectively) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-natural-history-and-prognosis\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Natural history and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H116969791\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of familial HCM includes LVH secondary to other disorders as well as other causes of HCM morphology such as amyloidosis (<a href=\"image.htm?imageKey=CARD%2F74268\" class=\"graphic graphic_table graphicRef74268 \">table 1B</a>). LVH is considered secondary when due to an identifiable disorder such as hypertension or aortic stenosis. As noted above, these disorders are not classified as cardiomyopathies. Secondary LVH is most commonly encountered as a complication of hypertension. The presence of LVH in a hypertensive subject increases the likelihood of cardiovascular morbidity and mortality [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/52\" class=\"abstract_t\">52</a>]. (See <a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension\" class=\"medical medical_review\">&quot;Clinical implications and treatment of left ventricular hypertrophy in hypertension&quot;</a> and <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation#H2599189\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;, section on 'Differential diagnosis of LVH'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Echocardiographic features of secondary left ventricular hypertrophy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echocardiography is the procedure of choice for identifying secondary LVH since the sensitivity of the various electrocardiographic (ECG) criteria may be as low as 7 to 35 percent with mild LVH and only 10 to 50 percent with moderate to severe disease [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=electrocardiographic-diagnosis-of-left-ventricular-hypertrophy\" class=\"medical medical_review\">&quot;Electrocardiographic diagnosis of left ventricular hypertrophy&quot;</a>.)</p><p>The hypertrophy is usually asymmetric in inherited hypertrophic cardiomyopathy, and symmetric in secondary disease [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/35,36,54,55\" class=\"abstract_t\">35,36,54,55</a>]. The predictive accuracy of the pattern of hypertrophy for genetically determined versus secondary hypertrophy, however, is low.</p><p>Historically, echocardiographic criteria for the diagnosis of LVH were largely based on M-mode echocardiography and included a LV mass index &ge;134 and &ge;110 <span class=\"nowrap\">g/m<sup>2</sup></span> body surface area in men and women, respectively (<a href=\"image.htm?imageKey=CARD%2F63653\" class=\"graphic graphic_figure graphicRef63653 \">figure 5</a> and <a href=\"image.htm?imageKey=CARD%2F58732%7ECARD%2F61196%7ECARD%2F61383%7ECARD%2F60104\" class=\"graphic graphic_diagnosticimage graphicRef58732 graphicRef61196 graphicRef61383 graphicRef60104 \">image 9A-D</a> and <a href=\"image.htm?imageKey=CARD%2F76903\" class=\"graphic graphic_waveform graphicRef76903 \">waveform 2</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/56,57\" class=\"abstract_t\">56,57</a>].However, M-mode echocardiography may not be ideally suited for this task because of a relatively low yield in older patients, suboptimal reproducibility, possible erroneous results in distorted ventricles, and use of a geometric algorithm that tends to overestimate mass. Two-dimensional echocardiography increase the precision and produce estimates of LV mass that more closely approximate values derived from pathology, magnetic resonance imaging, and computed tomography [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/58,59\" class=\"abstract_t\">58,59</a>].</p><p>The most commonly used 2D methods for measure of LV mass are area-length and truncated ellipse. Both methods have been previously validated and endorsed by the American Society of Echocardiography [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/60\" class=\"abstract_t\">60</a>]. The most recent American Society of Echocardiography published guidelines for diagnosis of LVH included criteria for mild, moderate, and severe LVH for men as 103 to 116, 117 to 130, &gt;130 <span class=\"nowrap\">g/m<sup>2</sup></span> and for women as 89 to 100, 101 to 112, &gt;112 <span class=\"nowrap\">g/m<sup>2</sup>,</span> respectively [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"abstract_t\">8</a>]. We consider LV mass index &gt;95 <span class=\"nowrap\">g/m<sup>2</sup></span> indicative of abnormally increased LV mass based on outcome data [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/61,62\" class=\"abstract_t\">61,62</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Sigmoid septum</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal apparent hypertrophy of the basal interventricular septum (known as sigmoid septum or angulated septum) occurs commonly in older adults, seemingly as the result of an age-related shift in the orientation of the LV long axis from vertical to horizontal. Contrast imaging of the LV suggests that there is little, if any, hypertrophy. Importantly, the axis shift of these hearts elongates the short axis view and can exaggerate calculated LV mass (by truncated ellipse or area length methods) to a degree that results in overestimation of the degree of hypertrophy. As a rule, if the LV wall is not thickened and LV volume is normal, an elevated calculated LV mass in a patient with sigmoid septum is likely artifactual. </p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">RESTRICTIVE CARDIOMYOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Restrictive cardiomyopathy is characterized by a nondilated (or small, end diastolic volume index &lt;40 <span class=\"nowrap\">mL/m<sup>2</sup>)</span> left ventricle (LV) with impaired ventricular filling [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/63\" class=\"abstract_t\">63</a>]. Hypertrophy is typically absent, although infiltrative disease (such as amyloidosis) and storage disease (such as Fabry disease) may cause an increase in LV wall thickness. Systolic function usually remains normal, at least early in the disease. This entity is a subset of what has been referred to as heart failure with preserved ejection fraction (HFpEF) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/64\" class=\"abstract_t\">64</a>]. Causes of restrictive cardiomyopathy include infiltrative disease (such as amyloidosis, hemochromatosis, or sarcoidosis), scleroderma, glycogen storage disease, and interstitial radiation fibrosis. (See <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies#H8\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;, section on 'Restrictive cardiomyopathy'</a>.)</p><p>Restrictive cardiomyopathies are more difficult to diagnose with echocardiography than dilated or hypertrophic cardiomyopathies, and may be challenging to distinguish from constrictive pericarditis. (See <a href=\"topic.htm?path=idiopathic-restrictive-cardiomyopathy\" class=\"medical medical_review\">&quot;Idiopathic restrictive cardiomyopathy&quot;</a>.)</p><p>Echocardiography, including Doppler interrogation, is the most effective noninvasive means for the recognition of this group of conditions. Restrictive cardiomyopathy is characterized by a low or normal diastolic volume, normal or only mildly reduced LV ejection fraction, atrial enlargement, normal pericardium, and abnormal diastolic function. Diastolic dysfunction is frequently restrictive, with an elevated peak mitral inflow velocity, rapid early mitral inflow deceleration, and reduced Doppler tissue imaging early annular velocity. (See <a href=\"topic.htm?path=differentiating-constrictive-pericarditis-and-restrictive-cardiomyopathy\" class=\"medical medical_review\">&quot;Differentiating constrictive pericarditis and restrictive cardiomyopathy&quot;</a>.)</p><p>Echocardiographic findings may help differentiate between restrictive cardiomyopathy and pericardial constriction among individuals with heart failure symptoms and normal LVEF. (See <a href=\"topic.htm?path=differentiating-constrictive-pericarditis-and-restrictive-cardiomyopathy\" class=\"medical medical_review\">&quot;Differentiating constrictive pericarditis and restrictive cardiomyopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Diabetes mellitus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Perhaps the most common restrictive cardiomyopathy is the small, stiff heart of diabetes in which diastolic dysfunction is the predominant functional abnormality [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/65\" class=\"abstract_t\">65</a>]. In the majority of diabetics, this condition is clinically unapparent [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/66,67\" class=\"abstract_t\">66,67</a>]. Quantitation of LV function reveals a normal ejection fraction and LV volumes that are lower than expected. This condition is suspected as a predisposing factor when, for example, diabetics with critical coronary artery stenosis and normal LV systolic function develop pulmonary congestion in association with angina or acute myocardial infarction. (See <a href=\"topic.htm?path=heart-failure-in-diabetes-mellitus\" class=\"medical medical_review\">&quot;Heart failure in diabetes mellitus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Amyloid cardiomyopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyloid cardiomyopathy can present as a restrictive cardiomyopathy or hypertrophic cardiomyopathy. The clinical manifestations and diagnosis of cardiac amyloidosis are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of amyloid cardiomyopathy&quot;</a>.)</p><p>Diastolic dysfunction is the most common, earliest, and most important echocardiographic abnormality in cardiac amyloidosis [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/68\" class=\"abstract_t\">68</a>].</p><p>Echocardiography in patients with overt cardiac amyloidosis frequently demonstrates symmetric LV wall thickening, typically involving the interventricular septum, small ventricular chambers, thickening of the atrial septum, pericardial effusion, and dilated atria (<a href=\"image.htm?imageKey=CARD%2F78406%7ECARD%2F59273\" class=\"graphic graphic_diagnosticimage graphicRef78406 graphicRef59273 \">image 10A-B</a> and <a href=\"image.htm?imageKey=CARD%2F61904%7ECARD%2F64330%7ECARD%2F78037\" class=\"graphic graphic_movie graphicRef61904 graphicRef64330 graphicRef78037 \">movie 3A-C</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Increased right ventricular wall thickness, when present, may be associated with right ventricular diastolic dysfunction, which can be demonstrated by Doppler examination [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/69\" class=\"abstract_t\">69</a>]. Disproportionate right ventricular enlargement may also occur [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/70\" class=\"abstract_t\">70</a>].</p><p>Another common echocardiographic finding in cardiac amyloidosis is a granular, &quot;speckled&quot; appearance of the myocardium, resulting from the presence of amyloid and collagen nodules in the heart (<a href=\"image.htm?imageKey=CARD%2F61904\" class=\"graphic graphic_movie graphicRef61904 \">movie 3A</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/68,71-73\" class=\"abstract_t\">68,71-73</a>]. This finding alone is relatively nonspecific [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/74\" class=\"abstract_t\">74</a>] but the combination of these refractile echoes, atrial septum thickening, and low ECG voltage are highly suggestive of cardiac amyloid [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/71\" class=\"abstract_t\">71</a>].</p><p>Apparent preservation or exaggeration of contractile function in a subgroup of patients with amyloid cardiomyopathy is explained by very low wall stress, which is the ultimate expression of afterload and is greatly reduced by the combination of thickened walls, very small cavity, and low generated systolic pressure (arterial hypotension). When contractile function is preserved, amyloid cardiomyopathy can be mistaken for hypertrophic cardiomyopathy and diagnosis can be delayed. A patient with low blood pressure, low ECG voltage, a pacemaker, and the above features should immediately arouse suspicion of the advanced stage of this form of lethal infiltrative cardiomyopathy. Early disease may be difficult to differentiate from other forms of cardiac disease and may only be manifest upon serial echocardiograms.</p><p>Strain echocardiography may be helpful in diagnosing amyloid cardiomyopathy. A systolic septal longitudinal base-to-apex strain ratio &gt;2.1 has an 88 percent sensitivity and 85 percent specificity in differentiating amyloid cardiomyopathy from other causes of LV hypertrophy [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/75\" class=\"abstract_t\">75</a>]. Polar maps (so-called &quot;bulls-eye&quot; maps) facilitate recognition of this unique pattern.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Endomyocardial fibrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endomyocardial fibrosis is a cause of restrictive cardiomyopathy in North Africa and South America. The condition is associated with eosinophilia in approximately 50 percent of those afflicted, and may overlap with eosinophilic endocarditis also known as Loeffler's or Davies disease when encountered in North Africa.</p><p>The recognition of endomyocardial fibrosis depends on a high level of clinical suspicion and characteristic echocardiographic appearance [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/76,77\" class=\"abstract_t\">76,77</a>]. There are mass-like apical lesions in the LV resulting from a thrombotic fibrocalcific process. These lesions are associated with restriction of LV and right ventricular filling due to obliteration of one or both cardiac apices (<a href=\"image.htm?imageKey=CARD%2F77099\" class=\"graphic graphic_diagnosticimage graphicRef77099 \">image 11</a>). In addition to the unique appearance of the apices, the atria are strikingly enlarged and mitral and tricuspid regurgitation are often present. As the condition progresses, more and more of the LV cavity is obliterated, leading to a progressively restrictive physiology (<a href=\"image.htm?imageKey=CARD%2F65132\" class=\"graphic graphic_diagnosticimage graphicRef65132 \">image 12</a>). (See <a href=\"topic.htm?path=endomyocardial-fibrosis\" class=\"medical medical_review\">&quot;Endomyocardial fibrosis&quot;</a>.)</p><p>Endomyocardial fibrosis can be differentiated from apical hypertrophic cardiomyopathy by left-sided echo contrast, which demonstrates obliteration of the apical cavity in the former and apical hypertrophy in the latter.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arrhythmogenic right ventricular cardiomyopathy (ARVC) or dysplasia (ARVD) is a category of cardiomyopathy characterized by fibrous or fibro-fatty replacement of myocardium in the inflow tract, outflow tract <span class=\"nowrap\">and/or</span> apex of the right ventricle. In its most severe form it is called Uhl's disease or parchment right ventricle. ARVC is difficult to diagnose by echocardiography due to limited sensitivity and specificity of echocardiographic features. The 2010 revised Task Force major echocardiographic criterion [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/78\" class=\"abstract_t\">78</a>] was developed to yield 95 percent specificity and requires regional right ventricular <span class=\"nowrap\">akinesis/dyskinesis</span> or aneurysm plus either right ventricular outflow dilatation or reduced fractional area change (<a href=\"image.htm?imageKey=CARD%2F64479%7ECARD%2F74268\" class=\"graphic graphic_table graphicRef64479 graphicRef74268 \">table 1A-B</a>) [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"abstract_t\">8</a>]. Minor echocardiographic criteria were selected to yield sensitivity equal to specificity. (See <a href=\"topic.htm?path=arrhythmogenic-right-ventricular-cardiomyopathy-diagnostic-evaluation-and-diagnosis#H3143755798\" class=\"medical medical_review\">&quot;Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis&quot;, section on 'Echocardiography'</a>.)</p><p>In a study using 2-D echocardiography, tricuspid annulus plane systolic excursion (TAPSE) and RV fractional area change predicted adverse outcomes [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/79\" class=\"abstract_t\">79</a>]. A study using 3-D echocardiography with Doppler tissue imaging demonstrated that patients with ARVC had lower right ventricular ejection fraction, decreased lateral right ventricular and LV systolic annular velocity, and decreased regional systolic strain compared with age-matched controls [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/80\" class=\"abstract_t\">80</a>]. In a study that included genotypically abnormal (desmosomal gene) relatives of ARVC probands (without phenotypic abnormality) and controls, reduced global and regional strain was present in patients with ARVC mutation but not in controls [<a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/81\" class=\"abstract_t\">81</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">UNCLASSIFIED CARDIOMYOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Left ventricular (LV) noncompaction and stress (takotsubo) cardiomyopathy lie in this category. </p><p>Stress cardiomyopathy is an often reversible form of cardiomyopathy that may present with slight troponin elevation and electrocardiogram abnormalities. Apical ballooning <span class=\"nowrap\">and/or</span> midventricular hypokinesis is usually seen. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy&quot;</a>.) </p><p>Isolated LV noncompaction is a cardiomyopathy characterized by prominent trabeculae and deep intertrabecular recesses. LV morphologic criteria for noncompaction should be applied with caution since the specificity of imaging criteria may be low in some populations such as athletes. (See <a href=\"topic.htm?path=isolated-left-ventricular-noncompaction\" class=\"medical medical_review\">&quot;Isolated left ventricular noncompaction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1979715\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Echocardiography is the primary diagnostic modality for identification and differentiation of the various types of cardiomyopathy (<a href=\"image.htm?imageKey=CARD%2F64479%7ECARD%2F74268\" class=\"graphic graphic_table graphicRef64479 graphicRef74268 \">table 1A-B</a>). (See <a href=\"#H15920411\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The five types of cardiomyopathy are dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassified cardiomyopathy. (See <a href=\"#H15920411\" class=\"local\">'Introduction'</a> above and <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies#H1978197\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;, section on 'Definition'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most distinctive two-dimensional echocardiographic findings in a dilated cardiomyopathy are left ventricular (LV) spherical dilatation, normal or reduced wall thickness, poor systolic wall thickening, <span class=\"nowrap\">and/or</span> reduced inward endocardial systolic motion (<a href=\"image.htm?imageKey=CARD%2F58760\" class=\"graphic graphic_figure graphicRef58760 \">figure 1</a> and <a href=\"image.htm?imageKey=CARD%2F65679%7ECARD%2F67315%7ECARD%2F50731%7ECARD%2F66421\" class=\"graphic graphic_diagnosticimage graphicRef65679 graphicRef67315 graphicRef50731 graphicRef66421 \">image 1A-D</a>). (See <a href=\"#H3\" class=\"local\">'Echocardiographic findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The echocardiographic diagnosis of hypertrophic cardiomyopathy (HCM) is based upon the finding of an otherwise unexplained hypertrophied, nondilated LV. A septal thickness &ge;15 mm has been commonly used to diagnose HCM, although other causes for hypertrophy must be excluded and some patients with HCM do not meet this threshold for septal thickness. (See <a href=\"#H15\" class=\"local\">'Hypertrophic cardiomyopathy'</a> above and <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restrictive cardiomyopathy is characterized by nondilated ventricles with impaired ventricular filling. Hypertrophy is typically absent, although infiltrative disease (such as amyloidosis) and storage disease (such as Fabry disease) may cause an increase in LV wall thickness. (See <a href=\"#H21\" class=\"local\">'Restrictive cardiomyopathy'</a> above and <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies#H8\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;, section on 'Restrictive cardiomyopathy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a category of cardiomyopathy characterized by fibrous or fibro-fatty replacement of myocardium in the inflow tract, outflow tract, <span class=\"nowrap\">and/or</span> apex of the right ventricle. Echocardiographic diagnosis of ARVC is difficult due to limited sensitivity and specificity. (See <a href=\"#H25\" class=\"local\">'Arrhythmogenic right ventricular cardiomyopathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The &quot;unclassified&quot; cardiomyopathies include LV noncompaction and stress cardiomyopathy. (See <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies#H11\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;, section on 'Unclassified cardiomyopathies'</a> and <a href=\"topic.htm?path=isolated-left-ventricular-noncompaction\" class=\"medical medical_review\">&quot;Isolated left ventricular noncompaction&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy&quot;</a>.) </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/1\" class=\"nounderline abstract_t\">Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/2\" class=\"nounderline abstract_t\">Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29:270.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/3\" class=\"nounderline abstract_t\">Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol 2013; 62:2046.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/4\" class=\"nounderline abstract_t\">Wasfy MM, Weiner RB. Differentiating the athlete's heart from hypertrophic cardiomyopathy. Curr Opin Cardiol 2015; 30:500.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/5\" class=\"nounderline abstract_t\">D'Ascenzi F, Pisicchio C, Caselli S, et al. RV Remodeling in Olympic Athletes. JACC Cardiovasc Imaging 2017; 10:385.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/6\" class=\"nounderline abstract_t\">Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/7\" class=\"nounderline abstract_t\">Gardin JM, Tommaso CL, Talano JV. Echographic early systolic partial closure (notching) of the aortic valve in congestive cardiomyopathy. Am Heart J 1984; 107:135.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/8\" class=\"nounderline abstract_t\">Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/9\" class=\"nounderline abstract_t\">McManus DD, Shah SJ, Fabi MR, et al. Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the Heart and Soul Study. J Am Soc Echocardiogr 2009; 22:190.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/10\" class=\"nounderline abstract_t\">White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/11\" class=\"nounderline abstract_t\">Sun JP, James KB, Yang XS, et al. Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities. Am J Cardiol 1997; 80:1583.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/12\" class=\"nounderline abstract_t\">de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32:948.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/13\" class=\"nounderline abstract_t\">Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000; 85:837.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/14\" class=\"nounderline abstract_t\">Ristow B, Ali S, Ren X, et al. Elevated pulmonary artery pressure by Doppler echocardiography predicts hospitalization for heart failure and mortality in ambulatory stable coronary artery disease: the Heart and Soul Study. J Am Coll Cardiol 2007; 49:43.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/15\" class=\"nounderline abstract_t\">Hoit BD. Left atrial size and function: role in prognosis. J Am Coll Cardiol 2014; 63:493.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/16\" class=\"nounderline abstract_t\">Maddukuri PV, Vieira ML, DeCastro S, et al. What is the best approach for the assessment of left atrial size? Comparison of various unidimensional and two-dimensional parameters with three-dimensional echocardiographically determined left atrial volume. J Am Soc Echocardiogr 2006; 19:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/17\" class=\"nounderline abstract_t\">Ristow B, Na B, Ali S, et al. Left ventricular outflow tract and pulmonary artery stroke distances independently predict heart failure hospitalization and mortality: the Heart and Soul Study. J Am Soc Echocardiogr 2011; 24:565.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/18\" class=\"nounderline abstract_t\">Loutfi H, Nishimura RA. Quantitative evaluation of left ventricular systolic function by Doppler echocardiographic techniques. Echocardiography 1994; 11:305.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/19\" class=\"nounderline abstract_t\">Kolias TJ, Aaronson KD, Armstrong WF. Doppler-derived dP/dt and -dP/dt predict survival in congestive heart failure. J Am Coll Cardiol 2000; 36:1594.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/20\" class=\"nounderline abstract_t\">Pozzoli M, Traversi E, Cioffi G, et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 1997; 95:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/21\" class=\"nounderline abstract_t\">Rihal CS, Nishimura RA, Hatle LK, et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 1994; 90:2772.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/22\" class=\"nounderline abstract_t\">Temporelli PL, Corr&agrave; U, Imparato A, et al. Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. J Am Coll Cardiol 1998; 31:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/23\" class=\"nounderline abstract_t\">Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22:808.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/24\" class=\"nounderline abstract_t\">Ren X, Ristow B, Na B, et al. Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol 2007; 99:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/25\" class=\"nounderline abstract_t\">Yotti R, Bermejo J, Antoranz JC, et al. A noninvasive method for assessing impaired diastolic suction in patients with dilated cardiomyopathy. Circulation 2005; 112:2921.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/26\" class=\"nounderline abstract_t\">Dini FL, Nuti R, Barsotti L, et al. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography 2002; 19:457.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/27\" class=\"nounderline abstract_t\">Dini FL, Michelassi C, Micheli G, Rovai D. Prognostic value of pulmonary venous flow Doppler signal in left ventricular dysfunction: contribution of the difference in duration of pulmonary venous and mitral flow at atrial contraction. J Am Coll Cardiol 2000; 36:1295.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/28\" class=\"nounderline abstract_t\">Zamorano J, P&eacute;rez de Isla L, Roque C, Khanhderia B. The role of echocardiography in the assessment of mechanical dyssynchrony and its importance in predicting response to prognosis after cardiac resynchronization therapy. J Am Soc Echocardiogr 2007; 20:91.</a></li><li class=\"breakAll\">Agler, DA. Cardiac resynchronization therapy and the emerging role of echocardiography (part 2): the comprehensive examination.</li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/30\" class=\"nounderline abstract_t\">Waggoner AD, Agler DA, Adams DB. Cardiac resynchronization therapy and the emerging role of echocardiography (part 1): indications and results from current studies. J Am Soc Echocardiogr 2007; 20:70.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/31\" class=\"nounderline abstract_t\">Bleeker GB, Schalij MJ, Boersma E, et al. Relative merits of M-mode echocardiography and tissue Doppler imaging for prediction of response to cardiac resynchronization therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2007; 99:68.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/32\" class=\"nounderline abstract_t\">Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/33\" class=\"nounderline abstract_t\">Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:e783.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/34\" class=\"nounderline abstract_t\">Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2733.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/35\" class=\"nounderline abstract_t\">Cir&oacute; E, Nichols PF 3rd, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Two-dimensional echocardiographic analysis. Circulation 1983; 67:1227.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/36\" class=\"nounderline abstract_t\">Maron BJ. Asymmetry in hypertrophic cardiomyopathy: the septal to free wall thickness ratio revisited. Am J Cardiol 1985; 55:835.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/37\" class=\"nounderline abstract_t\">Kereiakes DJ, Anderson DJ, Crouse L, Chatterjee K. Apical hypertrophic cardiomyopathy. Am Heart J 1983; 105:855.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/38\" class=\"nounderline abstract_t\">Maron BJ, Bonow RO, Seshagiri TN, et al. Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). Am J Cardiol 1982; 49:1838.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/39\" class=\"nounderline abstract_t\">Vacek JL, Davis WR, Bellinger RL, McKiernan TL. Apical hypertrophic cardiomyopathy in American patients. Am Heart J 1984; 108:1501.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/40\" class=\"nounderline abstract_t\">Otieno H, Vivas Y, Traub D, et al. Images in cardiovascular medicine: contrast echocardiography in apical hypertrophic cardiomyopathy. Circulation 2006; 114:e33.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/41\" class=\"nounderline abstract_t\">Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/42\" class=\"nounderline abstract_t\">Maron BJ, Gottdiener JS, Arce J, et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985; 6:1.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/43\" class=\"nounderline abstract_t\">Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/44\" class=\"nounderline abstract_t\">Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006; 47:1175.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/45\" class=\"nounderline abstract_t\">Chen S, Yuan J, Qiao S, et al. Evaluation of left ventricular diastolic function by global strain rate imaging in patients with obstructive hypertrophic cardiomyopathy: a simultaneous speckle tracking echocardiography and cardiac catheterization study. Echocardiography 2014; 31:615.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/46\" class=\"nounderline abstract_t\">Almaas VM, Haugaa KH, Str&oslash;m EH, et al. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy. Heart 2014; 100:631.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/47\" class=\"nounderline abstract_t\">Haland TF, Almaas VM, Hasselberg NE, et al. Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2016; 17:613.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/48\" class=\"nounderline abstract_t\">Badran HM, Faheem N, Ibrahim WA, et al. Systolic function reserve using two-dimensional strain imaging in hypertrophic cardiomyopathy: comparison with essential hypertension. J Am Soc Echocardiogr 2013; 26:1397.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/49\" class=\"nounderline abstract_t\">Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98:1442.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/50\" class=\"nounderline abstract_t\">Pollick C, Morgan CD, Gilbert BW, et al. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982; 66:1087.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/51\" class=\"nounderline abstract_t\">Reant P, Reynaud A, Pillois X, et al. Comparison of resting and exercise echocardiographic parameters as indicators of outcomes in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2015; 28:194.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/52\" class=\"nounderline abstract_t\">Leenen FH. Increased risk attributed to left ventricular hypertrophy in hypertension. Curr Opin Cardiol 1996; 11:464.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/53\" class=\"nounderline abstract_t\">Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation 1990; 81:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/54\" class=\"nounderline abstract_t\">Maron BJ, Nichols PF 3rd, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984; 53:1087.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/55\" class=\"nounderline abstract_t\">Nair CK, Kudesia V, Hansen D, et al. Echocardiographic and electrocardiographic characteristics of patients with hypertrophic cardiomyopathy with and without mitral anular calcium. Am J Cardiol 1987; 59:1428.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/56\" class=\"nounderline abstract_t\">Abergel E, Tase M, Bohlender J, et al. Which definition for echocardiographic left ventricular hypertrophy? Am J Cardiol 1995; 75:498.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/57\" class=\"nounderline abstract_t\">Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/58\" class=\"nounderline abstract_t\">Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens 1997; 15:801.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/59\" class=\"nounderline abstract_t\">Gopal AS, Schnellbaecher MJ, Shen Z, et al. Freehand three-dimensional echocardiography for measurement of left ventricular mass: in vivo anatomic validation using explanted human hearts. J Am Coll Cardiol 1997; 30:802.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/60\" class=\"nounderline abstract_t\">Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/61\" class=\"nounderline abstract_t\">Stevens SM, Farzaneh-Far R, Na B, et al. Development of an echocardiographic risk-stratification index to predict heart failure in patients with stable coronary artery disease: the Heart and Soul study. JACC Cardiovasc Imaging 2009; 2:11.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/62\" class=\"nounderline abstract_t\">Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol 2008; 102:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/63\" class=\"nounderline abstract_t\">Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/64\" class=\"nounderline abstract_t\">Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011; 124:e540.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/65\" class=\"nounderline abstract_t\">Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006; 48:1548.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/66\" class=\"nounderline abstract_t\">Bouchard A, Sanz N, Botvinick EH, et al. Noninvasive assessment of cardiomyopathy in normotensive diabetic patients between 20 and 50 years old. Am J Med 1989; 87:160.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/67\" class=\"nounderline abstract_t\">P&eacute;rez JE, McGill JB, Santiago JV, et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992; 19:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/68\" class=\"nounderline abstract_t\">Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63:188.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/69\" class=\"nounderline abstract_t\">Klein AL, Hatle LK, Burstow DJ, et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990; 15:99.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/70\" class=\"nounderline abstract_t\">Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80:486.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/71\" class=\"nounderline abstract_t\">Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987; 59:418.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/72\" class=\"nounderline abstract_t\">Nicolosi GL, Pavan D, Lestuzzi C, et al. Prospective identification of patients with amyloid heart disease by two-dimensional echocardiography. Circulation 1984; 70:432.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/73\" class=\"nounderline abstract_t\">Eriksson P, Eriksson A, Backman C, et al. Highly refractile myocardial echoes in familial amyloidosis with polyneuropathy. A correlative echocardiographic and histopathological study. Acta Med Scand 1985; 217:27.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/74\" class=\"nounderline abstract_t\">Bhandari AK, Nanda NC. Myocardial texture characterization by two-dimensional echocardiography. Am J Cardiol 1983; 51:817.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/75\" class=\"nounderline abstract_t\">Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 2013; 6:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/76\" class=\"nounderline abstract_t\">Acquatella H, Schiller NB. Echocardiographic recognition of Chagas' disease and endomyocardial fibrosis. J Am Soc Echocardiogr 1988; 1:60.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/77\" class=\"nounderline abstract_t\">Acquatella H, Schiller NB, Puigb&oacute; JJ, et al. Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983; 67:1219.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/78\" class=\"nounderline abstract_t\">Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121:1533.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/79\" class=\"nounderline abstract_t\">Saguner AM, Vecchiati A, Baldinger SH, et al. Different prognostic value of functional right ventricular parameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ Cardiovasc Imaging 2014; 7:230.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/80\" class=\"nounderline abstract_t\">Kjaergaard J, Hastrup Svendsen J, Sogaard P, et al. Advanced quantitative echocardiography in arrhythmogenic right ventricular cardiomyopathy. J Am Soc Echocardiogr 2007; 20:27.</a></li><li><a href=\"https://www.uptodate.com/contents/echocardiographic-recognition-of-cardiomyopathies/abstract/81\" class=\"nounderline abstract_t\">R&eacute;ant P, Hauer AD, Castelletti S, et al. Epicardial myocardial strain abnormalities may identify the earliest stages of arrhythmogenic cardiomyopathy. Int J Cardiovasc Imaging 2016; 32:593.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5330 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1979715\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H15920411\" id=\"outline-link-H15920411\">INTRODUCTION</a></li><li><a href=\"#H116968825\" id=\"outline-link-H116968825\">CLASSIFICATION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DILATED CARDIOMYOPATHY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Echocardiographic findings</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Left ventricular volume</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">End-systolic volume index</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Right ventricle</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Left atrium</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Doppler echocardiography</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Cardiac synchrony</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Features of specific types of dilated cardiomyopathy</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Ischemic cardiomyopathy</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Chagasic cardiomyopathy</a></li></ul></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">HYPERTROPHIC CARDIOMYOPATHY</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Echocardiographic features</a><ul><li><a href=\"#H348986279\" id=\"outline-link-H348986279\">- Strain echocardiography</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Provocative maneuvers</a></li></ul></li><li><a href=\"#H116969791\" id=\"outline-link-H116969791\">Differential diagnosis</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">- Echocardiographic features of secondary left ventricular hypertrophy</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Sigmoid septum</a></li></ul></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">RESTRICTIVE CARDIOMYOPATHY</a><ul><li><a href=\"#H22\" id=\"outline-link-H22\">Diabetes mellitus</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Amyloid cardiomyopathy</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Endomyocardial fibrosis</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">UNCLASSIFIED CARDIOMYOPATHY</a></li><li><a href=\"#H1979715\" id=\"outline-link-H1979715\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/5330|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/65679\" class=\"graphic graphic_diagnosticimage\">- Long axis view dilated CM</a></li><li><a href=\"image.htm?imageKey=CARD/67315\" class=\"graphic graphic_diagnosticimage\">- Echo normal and dilated cardiomyopathy</a></li><li><a href=\"image.htm?imageKey=CARD/50731\" class=\"graphic graphic_diagnosticimage\">- 2 D echo dilated cardiomyopathy</a></li><li><a href=\"image.htm?imageKey=CARD/66421\" class=\"graphic graphic_diagnosticimage\">- M-mode cardiomyopathy II</a></li><li><a href=\"image.htm?imageKey=CARD/66756\" class=\"graphic graphic_diagnosticimage\">- E point septal separation LVEF</a></li><li><a href=\"image.htm?imageKey=CARD/63276\" class=\"graphic graphic_diagnosticimage\">- M mode aorta dilated CM</a></li><li><a href=\"image.htm?imageKey=CARD/53355\" class=\"graphic graphic_diagnosticimage\">- M mode aorta cardiomyopathy</a></li><li><a href=\"image.htm?imageKey=CARD/72326\" class=\"graphic graphic_diagnosticimage\">- Estimation of LV volumes</a></li><li><a href=\"image.htm?imageKey=CARD/81391\" class=\"graphic graphic_diagnosticimage\">- Pulsed wave Doppler LV outflow</a></li><li><a href=\"image.htm?imageKey=CARD/51194\" class=\"graphic graphic_diagnosticimage\">- Trabeculations HCM</a></li><li><a href=\"image.htm?imageKey=CARD/78895\" class=\"graphic graphic_diagnosticimage\">- Long axis hypertrophic CM</a></li><li><a href=\"image.htm?imageKey=CARD/70534\" class=\"graphic graphic_diagnosticimage\">- M-mode obstructive HCM</a></li><li><a href=\"image.htm?imageKey=CARD/78856\" class=\"graphic graphic_diagnosticimage\">- Subcostal view HCM</a></li><li><a href=\"image.htm?imageKey=CARD/55693\" class=\"graphic graphic_diagnosticimage\">- Long axis HCM ASH SAM</a></li><li><a href=\"image.htm?imageKey=CARD/50651\" class=\"graphic graphic_diagnosticimage\">- M-mode hypertrophic CM</a></li><li><a href=\"image.htm?imageKey=CARD/51424\" class=\"graphic graphic_diagnosticimage\">- Provocable obstruction HCM</a></li><li><a href=\"image.htm?imageKey=CARD/75078\" class=\"graphic graphic_diagnosticimage\">- M mode aorta hypertrophic CM</a></li><li><a href=\"image.htm?imageKey=CARD/58732\" class=\"graphic graphic_diagnosticimage\">- Computer calculation of LV mass</a></li><li><a href=\"image.htm?imageKey=CARD/61196\" class=\"graphic graphic_diagnosticimage\">- Short axis LV mass</a></li><li><a href=\"image.htm?imageKey=CARD/61383\" class=\"graphic graphic_diagnosticimage\">- LVH M-mode echo</a></li><li><a href=\"image.htm?imageKey=CARD/60104\" class=\"graphic graphic_diagnosticimage\">- 4 chamber view LV mass</a></li><li><a href=\"image.htm?imageKey=CARD/78406\" class=\"graphic graphic_diagnosticimage\">- M mode amyloid cardiomyopathy</a></li><li><a href=\"image.htm?imageKey=CARD/59273\" class=\"graphic graphic_diagnosticimage\">- Apical 4-chamber amylodosis</a></li><li><a href=\"image.htm?imageKey=CARD/77099\" class=\"graphic graphic_diagnosticimage\">- Echo endomyocardial fibrosis</a></li><li><a href=\"image.htm?imageKey=CARD/65132\" class=\"graphic graphic_diagnosticimage\">- RV endomyocardial fibrosis</a></li></ul></li><li><div id=\"CARD/5330|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/58760\" class=\"graphic graphic_figure\">- M-mode cardiomyopathy I</a></li><li><a href=\"image.htm?imageKey=CARD/68362\" class=\"graphic graphic_figure\">- Sites LV measurements</a></li><li><a href=\"image.htm?imageKey=CARD/70139\" class=\"graphic graphic_figure\">- Algorithms LV volume</a></li><li><a href=\"image.htm?imageKey=CARD/58156\" class=\"graphic graphic_figure\">- Morphologic variants HCM</a></li><li><a href=\"image.htm?imageKey=CARD/67484\" class=\"graphic graphic_figure\">- Pulsed Doppler HCM</a></li><li><a href=\"image.htm?imageKey=CARD/63653\" class=\"graphic graphic_figure\">- Estimation of LV mass</a></li></ul></li><li><div id=\"CARD/5330|MOV\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"MOVIES\">MOVIES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/78668\" class=\"graphic graphic_movie\">- Dilated cardiomyopathy four chamber echocardiogram</a></li><li><a href=\"image.htm?imageKey=CARD/75021\" class=\"graphic graphic_movie\">- Dilated cardiomyopathy long axis echocardiogram</a></li><li><a href=\"image.htm?imageKey=CARD/68493\" class=\"graphic graphic_movie\">- Dilated cardiomyopathy short axis echocardiogram</a></li><li><a href=\"image.htm?imageKey=CARD/79426\" class=\"graphic graphic_movie\">- Apical three-chamber echo HCM</a></li><li><a href=\"image.htm?imageKey=CARD/65618\" class=\"graphic graphic_movie\">- Long axis echo HCM</a></li><li><a href=\"image.htm?imageKey=CARD/61904\" class=\"graphic graphic_movie\">- Cardiac amyloidosis four chamber echocardiogram</a></li><li><a href=\"image.htm?imageKey=CARD/64330\" class=\"graphic graphic_movie\">- Cardiac amyloidosis parasternal long axis echocardiogram</a></li><li><a href=\"image.htm?imageKey=CARD/78037\" class=\"graphic graphic_movie\">- Cardiac amyloidosis short axis echocardiogram</a></li></ul></li><li><div id=\"CARD/5330|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/64479\" class=\"graphic graphic_table\">- ESC 2008 CM familial</a></li><li><a href=\"image.htm?imageKey=CARD/74268\" class=\"graphic graphic_table\">- ESC 2008 CM nonfamilial</a></li><li><a href=\"image.htm?imageKey=CARD/72146\" class=\"graphic graphic_table\">- Doppler diastolic dysfunction</a></li></ul></li><li><div id=\"CARD/5330|Waveform\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"WAVEFORMS\">WAVEFORMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/59321\" class=\"graphic graphic_waveform\">- Doppler transmitral inflow pattern</a></li><li><a href=\"image.htm?imageKey=CARD/76903\" class=\"graphic graphic_waveform\">- M-mode echocardiography LV hypertrophy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=arrhythmogenic-right-ventricular-cardiomyopathy-anatomy-histology-and-clinical-manifestations\" class=\"medical medical_review\">Arrhythmogenic right ventricular cardiomyopathy: Anatomy, histology, and clinical manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=arrhythmogenic-right-ventricular-cardiomyopathy-diagnostic-evaluation-and-diagnosis\" class=\"medical medical_review\">Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-dilated-cardiomyopathy\" class=\"medical medical_review\">Causes of dilated cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Chagas heart disease: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension\" class=\"medical medical_review\">Clinical implications and treatment of left ventricular hypertrophy in hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">Clinical manifestations and diagnosis of amyloid cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy\" class=\"medical medical_review\">Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies\" class=\"medical medical_review\">Definition and classification of the cardiomyopathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=determining-the-etiology-and-severity-of-heart-failure-or-cardiomyopathy\" class=\"medical medical_review\">Determining the etiology and severity of heart failure or cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differentiating-constrictive-pericarditis-and-restrictive-cardiomyopathy\" class=\"medical medical_review\">Differentiating constrictive pericarditis and restrictive cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=echocardiographic-evaluation-of-left-ventricular-diastolic-function\" class=\"medical medical_review\">Echocardiographic evaluation of left ventricular diastolic function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=echocardiographic-evaluation-of-the-mitral-valve\" class=\"medical medical_review\">Echocardiographic evaluation of the mitral valve</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=electrocardiographic-diagnosis-of-left-ventricular-hypertrophy\" class=\"medical medical_review\">Electrocardiographic diagnosis of left ventricular hypertrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endomyocardial-fibrosis\" class=\"medical medical_review\">Endomyocardial fibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-dilated-cardiomyopathy-prevalence-diagnosis-and-treatment\" class=\"medical medical_review\">Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=heart-failure-in-diabetes-mellitus\" class=\"medical medical_review\">Heart failure in diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation\" class=\"medical medical_review\">Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertrophic-cardiomyopathy-gene-mutations-and-clinical-genetic-testing\" class=\"medical medical_review\">Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertrophic-cardiomyopathy-morphologic-variants-and-the-pathophysiology-of-left-ventricular-outflow-tract-obstruction\" class=\"medical medical_review\">Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertrophic-cardiomyopathy-natural-history-and-prognosis\" class=\"medical medical_review\">Hypertrophic cardiomyopathy: Natural history and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=idiopathic-restrictive-cardiomyopathy\" class=\"medical medical_review\">Idiopathic restrictive cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ischemic-cardiomyopathy-treatment-and-prognosis\" class=\"medical medical_review\">Ischemic cardiomyopathy: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isolated-left-ventricular-noncompaction\" class=\"medical medical_review\">Isolated left ventricular noncompaction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=predictors-of-survival-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Predictors of survival in heart failure with reduced ejection fraction</a></li></ul></div></div>","javascript":null}